Negative in Ames (4 assays), CHL chromosome aberration, mouse micronucleus and rat UDS assays
“Istradefylline was negative in 4 Ames assays for bacterial mutagenicity, the chromosomal aberration assay in Chinese hamster lung cells, the micronucleus assay in mice or the UDS assay in rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 143Source ↗
Carcinogenicity
Lifetime oral studies in mouse and rat: no evidence of carcinogenicity
“In lifetime oral carcinogenicity studies, there was no evidence of carcinogenicity in mouse (0, 25, 125, or 250 mg/kg) or rat (0, 30, 100, or 320 mg/kg).”
Teratogenic, with embryofetal and offspring mortality and growth deficits at clinically relevant exposures, without maternal toxicity
“oral administration of istradefylline during pregnancy resulted in teratogenicity (increased incidences of fetal structural abnormalities, embryofetal and offspring mortality and growth deficits) at clinically relevant exposures and in the absence of maternal toxicity.”
No QT or respiratory effects in telemetered dogs at 1000 mg/kg; no hERG inhibition up to 2 µM
“In a later study, telemeterized dogs were treated for 6 weeks at 1000 mg/kg p.o. daily and no significant effects were reported on the QT interval or respiratory parameters. The in vitro hERG assay showed no inhibition of the Ikr current at concentrations up to 2 µmol/L.”
✓ VerifiedFDA pharmacology/toxicology review, p. 34Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative